SCHEMBL4858843

SCHEMBL4858843

COc1ccc(-c2ccc3c(c2)CCN3C(=O)c2ccccc2)cc1CCN(CCCCC=O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.44
CYP11B2 P19099 2/20 0.42
LMNA P02545 5/20 0.42
CYP11B1 P15538 1/20 0.42
MAPT P10636 4/20 0.41
TP53 P04637 4/20 0.41
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39
TUBB6 Q9BUF5 1/20 0.39
TUBB2B Q9BVA1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859154 0.91 THRB (0.41) THRBCYP11B2LMNACYP11B1MAPT
SCHEMBL4858572 0.90 CYP11B1 (0.44) CYP11B2LMNACYP11B1MAPTTRIM24
SCHEMBL4858164 0.88 DGAT1 (0.46) THRBMAPTTP53TRIM24RAB9A
SCHEMBL4858694 0.87 TRIM24 (0.46) CYP11B2LMNACYP11B1TRIM24SMN1; SMN2
SCHEMBL4861459 0.87 MEN1 (0.34) CYP11B2CYP11B1TRIM24
SCHEMBL4851761 0.87 TRIM24 (0.36) THRBCYP11B2LMNACYP11B1TRIM24
SCHEMBL4859687 0.86 ADRB3 (0.38) MAPT
SCHEMBL4859365 0.85 NOTUM (0.35) CYP11B2CYP11B1TRIM24SMN1; SMN2
SCHEMBL4860206 0.83 S1PR1 (0.40) MAPT
SCHEMBL4851559 0.81 NOTUM (0.41) CYP11B2LMNACYP11B1MAPTTRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462628-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-09 US disclosed
US-7138533-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-11-21 US disclosed
US-7132547-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-11-07 US disclosed
US-20060211675-A1 Preventives/remedies for urinary disturbance ISHIHARA YUJI 2006-09-21 US disclosed
US-20060063769-A1 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-03-23 US disclosed
US-20050197362-A1 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-09-08 US disclosed
EP-1466625-A1 PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE Takeda Chemical Industries, Ltd. (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063769-A1 Preventives/remedies for urinary disturbance ACHE, BPHL, CHRM1 THRB 1908/4885CYP11B2 872/4885LMNA 1921/4885
US-20050197362-A1 Preventives/remedies for urinary disturbance ACHE, BPHL, CHRM1 THRB 1908/4885CYP11B2 872/4885LMNA 1921/4885
US-20060211675-A1 Preventives/remedies for urinary disturbance ACHE, BPHL, ACE THRB 3542/4885CYP11B2 655/4885LMNA 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.